Previous close | 91.38 |
Open | 96.00 |
Bid | 0.00 x N/A |
Ask | 0.00 x N/A |
Day's range | 88.30 - 96.00 |
52-week range | 85.38 - 125.74 |
Volume | |
Avg. volume | 3,839 |
Market cap | 25.171B |
Beta (5Y monthly) | 0.24 |
PE ratio (TTM) | 5.08 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | 06 Jun 2022 |
1y target est | N/A |
BioNTech stock lifted a fraction Monday after Covid vaccine sales dropped again in the first quarter, amid wide losses.
Monday, BioNTech SE (NASDAQ:BNTX) reported a first-quarter EPS loss of 1.31 euros ($1.41 loss), a shift from an income of 2.05 euros, missing the consensus loss of 97 cents. The COVID-19 vaccine maker reported sales of 187.6 million euros (roughly $202 million), down from 1.3 billion euros reported a year ago, missing the consensus of 427.5 million euros. The European biotech firm posted a quarterly net loss of 315 million euros, compared with a profit of 502 million a year earlier. “We expect t
The pharmaceutical company posts a first-quarter loss of €1.31 a share, a swing from year-earlier profit of €2.05.